{"id":"chop","rwe":[],"_fda":{"id":"41d661c2-82f9-0a2d-e063-6294a90a49ee","set_id":"2786cec8-0b8e-9c83-e063-6394a90ab338","openfda":{"upc":["0182740000028"],"unii":["G63QQF2NOX","4Y5P7MUD51","4X49Y0596W","5A68WGF6WM"],"route":["TOPICAL"],"spl_id":["41d661c2-82f9-0a2d-e063-6294a90a49ee"],"brand_name":["AVOBENZONE,OCTINOXATE,OCTISALATE,OCTOCRYLENE"],"spl_set_id":["2786cec8-0b8e-9c83-e063-6394a90ab338"],"package_ndc":["83724-770-01"],"product_ndc":["83724-770"],"generic_name":["CHOP SAVER FRESH CITRUS SPF 15 LIP BALM"],"product_type":["HUMAN OTC DRUG"],"substance_name":["AVOBENZONE","OCTINOXATE","OCTISALATE","OCTOCRYLENE"],"manufacturer_name":["Good for the Goose Products, LLC"],"application_number":["M020"],"is_original_packager":[true]},"purpose":["Purpose: Sunscreen"],"version":"2","stop_use":["Stop use and ask a doctor if rash occurs"],"warnings":["Warnings: Do not use on damaged or broken skin When using this product, keep out of eyes Stop use and ask a doctor if rash occurs Keep out of reach of children."],"questions":["Questions or comments? 877-346-0951"],"do_not_use":["Do not use on damaged or broken skin"],"when_using":["When using this product, keep out of eyes"],"effective_time":"20251023","active_ingredient":["Active Ingredients: Avobenzone 2%, Octinoxate 6.5% Octisalate 5%, Octocrylene 1.5%"],"inactive_ingredient":["Inactive Ingredients: Castor Oil*, Candelilla Wax, Beeswax*, Aloe Vera*, Calendula*, Comfrey*, Raspberry Leaf*, Willow Bark*, Ginger Root*, Shea Butter*, Mango Butter*, Carnauba Wax*, Avocado Oil*, Arnica Extract, Lemon Essential Oil*, Vitamin E, Grapefruit Essential Oil, Orange Essential Oil*, Lime Essential Oil*, Ginger Essential Oil*, Pea Isolate *Certified Organic Ingredient"],"recent_major_changes":["Dosage and Administration section updated to read: Directions: apply liberally 15 minutes before sun exposure reapply at least every 2 hours use a water-resistant sunscreen if swimming or sweating Sun protection measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10am-2pm. wear long-sleeved shirts, pants, hats and sunglasses children under 6 months of age: ask a doctor"],"storage_and_handling":["Other information: Protect this product from excessive heat and direct sun"],"indications_and_usage":["Use: Helps prevent sunburn"],"spl_unclassified_section":["Drug Facts","Blister Card Content SPF 15 Broad Spectrum Fresh Citrus Gosling's Original ChopSaver Lip Care 10 Certified Organic Ingredients Musician Invented Dermatologist Recommended with soothing arnica sunflower extract W hen you're a proefessional trumpet player like I am, healthy lips are essential. That's why I created ChopSaver- a lip care alternative that's dermatologist-recommended and musician-trusted. I'm confident ChopSaver will work for you , too. -Dan Gosling, ChopSaver Inventor Broad Spectrum SPF 15 Sunscreen Visit us at www.chopsaver.com (c) 2019 Good For the Goose Products, LLC P.O. Box 20692 - Indianapolis, IN 46220 Made in the USA with domestic and imported ingredients Net Wt. .15 oz (4.25 g)","Tube Label Content Peel here for Drug Facts SPF 15 Broad Spectrum Gosling's Original ChopSaver Lip Care Broad Spectrum SPF 15 Sunscreen ChopSaver Lip Balm Made in the USA Net Wt. .15 oz (4.25 g)"],"dosage_and_administration":["Directions: apply liberally 15 minutes before sun exposure reapply at least every 2 hours use a water-resistant sunscreen if swimming or sweating Sun protection measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10am-2pm. wear long-sleeved shirts, pants, hats and sunglasses children under 6 months of age: ask a doctor"],"spl_product_data_elements":["AVOBENZONE,OCTINOXATE,OCTISALATE,OCTOCRYLENE Chop Saver Fresh Citrus SPF 15 Lip Balm CASTOR OIL CANDELILLA WAX YELLOW WAX SHEA BUTTER MANGIFERA INDICA SEED BUTTER CARNAUBA WAX AVOCADO OIL APRICOT KERNEL OIL GRAPE SEED OIL LEMON OIL, DISTILLED .ALPHA.-TOCOPHEROL GRAPEFRUIT OIL ORANGE OIL, DISTILLED LIME OIL, DISTILLED GINGER OIL ARNICA MONTANA WHOLE CALENDULA OFFICINALIS FLOWER RUBUS IDAEUS LEAF COMFREY LEAF ALOE VERA LEAF SALIX ALBA WHOLE PEA PROTEIN AVOBENZONE AVOBENZONE OCTINOXATE OCTINOXATE OCTISALATE OCTISALATE OCTOCRYLENE OCTOCRYLENE"],"keep_out_of_reach_of_children":["Keep out of reach of children."],"package_label_principal_display_panel":["Blister Card artwork Chop Saver Lip Care Broad Spectrum SPF 15 Sunscreen Lip Balm Blister Card Artwork","Tube Label Artwork Chop Saver Lip Care Broad Spectrum SPF 15 Sunscreen Lip Balm Label Artwork"]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Active","category":"status"},{"label":"sunburn","category":"indication"},{"label":"Good for the Goose Products, LLC","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[]},"trials":[],"aliases":["cyclophosphamide","doxorubicin","vincristine","prednisone","Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone"],"company":"Good for the Goose Products, LLC","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHOP","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:34:21.434220+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:34:42.179334+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:34:30.096828+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHOP","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:34:30.486425+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:20.296078+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:36.142060+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:20.296106+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M020","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:34:20.296109+00:00"}},"allNames":"avobenzone,octinoxate,octisalate,octocrylene","offLabel":[],"synonyms":["Avobenzone,Octinoxate,Octisalate,Octocrylene","AVOBENZONE"],"timeline":[],"aiSummary":"CHOP, a combination of Avobenzone, Octinoxate, Octisalate, and Octocrylene, is a marketed sunscreen product by Good for the Goose Products, LLC, designed to prevent sunburn. The key strength of CHOP lies in its multi-component formulation that effectively absorbs and reflects UV radiation, providing broad-spectrum protection. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic formulations.","approvals":[],"brandName":"Avobenzone,Octinoxate,Octisalate,Octocrylene","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Avobenzone, Octinoxate, Octisalate, and Octocrylene are UV filters that absorb or reflect UVA and UVB radiation, preventing it from penetrating the skin and causing damage. They work by absorbing energy from UV radiation and converting it into heat, which is then dissipated from the skin."},"commercial":{},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"CHOP\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=chop","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chop","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:26:48.353061","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:34:42.179425+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"chop","indications":{"approved":[{"id":"chop-sunburn-prevention","name":"Sunburn prevention","dosing":null,"approvals":[],"diseaseId":"","eligibility":"General population","pivotalTrial":null,"restrictions":[],"patientPopulation":"General population","diagnosticRequired":null,"brandNameForIndication":"Avobenzone,Octinoxate,Octisalate,Octocrylene"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":349,"completionDate":"2026-12-31"},{"nctId":"NCT03984448","phase":"PHASE2,PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double-Expressor Lymphoma","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":363,"completionDate":"2028-04-01"},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)","CD5 Positive"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT07496229","phase":"PHASE1,PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":["T-cell Lymphomas"],"enrollment":165,"completionDate":"2029-12"},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":1046,"completionDate":"2032-03-29"},{"nctId":"NCT07493109","phase":"PHASE3","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-05-30","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"enrollment":200,"completionDate":"2030-09-30"},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"enrollment":50,"completionDate":"2029-12-30"},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":["Follicular Lymphoma (FL)"],"enrollment":109,"completionDate":"2031-02-20"},{"nctId":"NCT07488806","phase":"","title":"Natural History Study for Patients With Nemaline Myopathy in Spain","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2026-06","conditions":["Nemaline Myopathy","Myopathies","Myopathic Conditions","NEB","ACTA1","TPM2","TPM3","TNNT1","CFL2","KBTBD13","KLHL40","KLHL41","LMOD3","Cohort Studies","MYPN","TNNT3"],"enrollment":100,"completionDate":"2032-06"},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":["Large B-cell Lymphoma"],"enrollment":420,"completionDate":"2033-07-28"},{"nctId":"NCT07483957","phase":"","title":"Linear vs. Circular Stapled Gastrojejunal Anastomosis in Bariatric Laparoscopic Gastric Bypass Surgery in Switzerland","status":"COMPLETED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2015-01-01","conditions":["Bariatric Surgery (Gastric Bypass)"],"enrollment":21375,"completionDate":"2025-05-15"},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":["Untreated Follicular Lymphoma"],"enrollment":1018,"completionDate":"2031-11-26"},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":["Relapsed or Refractory Follicular Lymphoma"],"enrollment":0,"completionDate":"2031-10-16"},{"nctId":"NCT07476105","phase":"NA","title":"Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":["Diffuse Large B Cell Lymphoma","Follicular Lymphoma Grade 3B"],"enrollment":170,"completionDate":"2029-05"},{"nctId":"NCT07123961","phase":"PHASE2","title":"Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-11-07","conditions":["Acute Respiratory Distress Syndrome (ARDS)","Ventilator Management","Lung-protective Ventilation","Pediatric Acute Respiratory Distress Syndrome (PARDS)"],"enrollment":160,"completionDate":"2030-06-30"},{"nctId":"NCT04473222","phase":"NA","title":"Behavioral Sleep Intervention in Urban Primary Care: Aim 3","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-10-16","conditions":["Sleep Disturbance","Sleep Deprivation","Sleep"],"enrollment":103,"completionDate":"2023-07-31"},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":["Lymphoma"],"enrollment":571,"completionDate":"2025-12"},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":["Follicular Lymphoma (FL)"],"enrollment":822,"completionDate":"2029-11-03"},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":["Mantle-cell Lymphoma"],"enrollment":55,"completionDate":"2028-12-15"},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":["Lymphoma","Lymphoma, Large B-Cell, Diffuse"],"enrollment":41,"completionDate":"2029-09-15"},{"nctId":"NCT04623541","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter's Syndrome","Treatment-naïve High Risk Chronic Lymphocytic Leukemia"],"enrollment":195,"completionDate":"2028-02"},{"nctId":"NCT04663347","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":543,"completionDate":"2027-09-30"},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":["High-risk Large B-cell Lymphoma (LBCL)"],"enrollment":300,"completionDate":"2031-03"},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":["Follicular Lymphoma (FL)"],"enrollment":1095,"completionDate":"2037-11"},{"nctId":"NCT04542824","phase":"PHASE1,PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":["Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma"],"enrollment":78,"completionDate":"2027-09"},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":3,"completionDate":"2026-12-31"},{"nctId":"NCT07437833","phase":"NA","title":"Psychophysiological Responses to Six Single-Session Self-Regulation Interventions in a Female Adult With ADHD and Stabilized Bipolar Disorder","status":"NOT_YET_RECRUITING","sponsor":"Poznan University of Physical Education","startDate":"2026-04-01","conditions":["ADHD - Attention Deficit Disorder With Hyperactivity","Bipolar Affective Disorder; Remission in"],"enrollment":1,"completionDate":"2026-08-31"},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":["Non-Hodgkin's Lymphoma","Diffuse Large B-Cell Lymphoma","DLBCL","NHL"],"enrollment":132,"completionDate":"2030-03-31"},{"nctId":"NCT04869657","phase":"NA","title":"Sustainment of Mental Health Supports","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-09-17","conditions":["Behavior Disorders"],"enrollment":421,"completionDate":"2025-07-01"},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":["Solid Tumors","Lymphoma"],"enrollment":40,"completionDate":"2027-10"},{"nctId":"NCT06630091","phase":"PHASE2","title":"A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-21","conditions":["Peripheral T Cell Lymphoma"],"enrollment":30,"completionDate":"2029-07-05"},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":["Lymphoma"],"enrollment":46,"completionDate":"2026-09-30"},{"nctId":"NCT04214444","phase":"PHASE3","title":"Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2020-07-03","conditions":["Pneumococcal Infections","Lymphoma, Large B-Cell, Diffuse"],"enrollment":26,"completionDate":"2025-05-14"},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":42,"completionDate":"2028-04"},{"nctId":"NCT07399301","phase":"NA","title":"High-Intensity Functional Training on Physical Performance and Mental Health in Elderly With Sarcopenia","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":["Geriatric Sarcopenia"],"enrollment":60,"completionDate":"2026-07-01"},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":["Large B-cell Lymphoma"],"enrollment":850,"completionDate":"2029-11-20"},{"nctId":"NCT07398638","phase":"PHASE1,PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":["Diffuse Large B Cell Lymphoma (DLBCL)"],"enrollment":122,"completionDate":"2031-02-28"},{"nctId":"NCT03758989","phase":"PHASE2","title":"A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2019-05-08","conditions":["DLBCL"],"enrollment":40,"completionDate":"2027-06-01"},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":1000,"completionDate":"2026-04-30"},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":["Follicular Lymphoma (FL)"],"enrollment":733,"completionDate":"2029-07-29"},{"nctId":"NCT04850495","phase":"PHASE1","title":"Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"Yazeed Sawalha","startDate":"2021-11-16","conditions":["Diffuse Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":38,"completionDate":"2026-06-15"},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)"],"enrollment":904,"completionDate":"2029-09-02"},{"nctId":"NCT05993091","phase":"NA","title":"Mirror Therapy and Augmented Reality in Stroke Rehabilitation","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-05-05","conditions":["Stroke Rehabilitation"],"enrollment":75,"completionDate":"2026-12-31"},{"nctId":"NCT06564038","phase":"PHASE1,PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":["Chronic Lymphocytic Leukaemia","Small Lymphocytic Lymphoma","Mantle-cell Lymphoma","Large B-cell Lymphoma","B-cell Non-Hodgkin Lymphoma"],"enrollment":276,"completionDate":"2028-02-28"},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":["Lymphoma, B-Cell"],"enrollment":174,"completionDate":"2028-12-01"},{"nctId":"NCT05782374","phase":"","title":"Real World Data on Ibrutinib Use in PCNSL Rel/Ref","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2022-08-10","conditions":["PCNSL"],"enrollment":36,"completionDate":"2026-08-10"},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Indolent Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2028-05-16"},{"nctId":"NCT06829771","phase":"PHASE1,PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":90,"completionDate":"2026-12"},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":["Diffuse Large B Cell Lymphoma","DLBCL","Cancer"],"enrollment":27,"completionDate":"2027-02"},{"nctId":"NCT07372365","phase":"PHASE2","title":"Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-10-24","conditions":["Marginal Zone Lymphoma (MZL)"],"enrollment":23,"completionDate":"2030-10-01"},{"nctId":"NCT06846463","phase":"PHASE2","title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-05-27","conditions":["Diffuse Large B-cell Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma"],"enrollment":21,"completionDate":"2032-07-31"},{"nctId":"NCT07348575","phase":"PHASE3","title":"A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-07-01","conditions":["Lymphoma, Large-Cell, Diffuse"],"enrollment":80,"completionDate":"2028-07-01"},{"nctId":"NCT02633878","phase":"PHASE3","title":"Chinese Herbal Medicine (New \"Shoutai Wan\") and/or Oral Progesterone Intervention Trial for Threatened Miscarriage","status":"COMPLETED","sponsor":"Heilongjiang University of Chinese Medicine","startDate":"2017-10-20","conditions":["Threatened Miscarriage"],"enrollment":1656,"completionDate":"2025-12-31"},{"nctId":"NCT07335120","phase":"","title":"A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma","status":"RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2024-10-30","conditions":["DLBCL"],"enrollment":800,"completionDate":"2028-10-30"},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":["Lymphoma, Follicular"],"enrollment":90,"completionDate":"2028-11-27"},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":["Lymphoma","Peripheral T Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma"],"enrollment":24,"completionDate":"2032-10-01"},{"nctId":"NCT07319702","phase":"NA","title":"Proprioceptive Neuromuscular Facilitation Combined With Spiral Muscle Chain Training for Pediatric Scoliosis","status":"COMPLETED","sponsor":"Nie danning","startDate":"2024-03-05","conditions":["Adolescent Idiopathic Scoliosis (AIS)"],"enrollment":189,"completionDate":"2024-12-30"},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":["DLBCL - Diffuse Large B Cell Lymphoma"],"enrollment":324,"completionDate":"2028-12-15"},{"nctId":"NCT03463057","phase":"PHASE2","title":"The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-08-30","conditions":["NHL","DLBCL"],"enrollment":109,"completionDate":"2027-01"},{"nctId":"NCT06141772","phase":"NA","title":"Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2023-12-21","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":24,"completionDate":"2025-04-10"},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":260,"completionDate":"2030-12"},{"nctId":"NCT05816850","phase":"","title":"Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-09-19","conditions":["Follicular Lymphoma"],"enrollment":654,"completionDate":"2027-06-01"},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":["DLBCL"],"enrollment":75,"completionDate":"2027-07"},{"nctId":"NCT03473249","phase":"PHASE4","title":"Effectiveness of Contrast-Enhanced Ultrasound","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-05-09","conditions":["Abdominal Injuries","Physical Abuse","Accidental Fall","Motor Vehicle Injury"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":611,"completionDate":"2027-02-01"},{"nctId":"NCT04696692","phase":"NA","title":"Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2021-02-09","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":60,"completionDate":"2025-12-11"},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":["Marginal Zone Lymphoma"],"enrollment":260,"completionDate":"2032-09"},{"nctId":"NCT04661007","phase":"PHASE1,PHASE2","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences Japan GK","startDate":"2020-12-15","conditions":["Non Hodgkins Lymphoma","Diffuse Large B-cell Lymphoma"],"enrollment":72,"completionDate":"2026-12-31"},{"nctId":"NCT05455697","phase":"PHASE1,PHASE2","title":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-01-26","conditions":["Diffuse Large B-Cell Lymphoma","Grade 3b Follicular Lymphoma","High Grade B-Cell Lymphoma"],"enrollment":35,"completionDate":"2027-07-06"},{"nctId":"NCT04594798","phase":"PHASE2","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2021-09-20","conditions":["DLBCL","Lymphoma, B-Cell"],"enrollment":39,"completionDate":"2026-07-31"},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":["Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Follicular Helper T-Cell Lymphoma, Follicular-Type","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":20,"completionDate":"2027-03-31"},{"nctId":"NCT07262099","phase":"NA","title":"Study of Effects of Dao-yin Exercise on the Patients With Breast Cancer Post Operation and Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-01-13","conditions":["Breast Cancer"],"enrollment":150,"completionDate":"2019-11-08"},{"nctId":"NCT06186648","phase":"PHASE2","title":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-03-21","conditions":["Richter Syndrome"],"enrollment":40,"completionDate":"2027-03-01"},{"nctId":"NCT07026630","phase":"NA","title":"Activities of Daily Living (ADL) Virtual Reality (VR) for Acquired Brain Injury (ABI) Upper-Limb Rehabilitation","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2025-11","conditions":["Upper Limb Rehabilitation","Stroke"],"enrollment":0,"completionDate":"2027-05"},{"nctId":"NCT06421948","phase":"PHASE1,PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":["Peripheral T-cell Lymphoma"],"enrollment":134,"completionDate":"2027-12-31"},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":["Follicular Lymphoma"],"enrollment":400,"completionDate":"2030-07-31"},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":["Non-Hodgkin's Lymphoma","Hematopoietic Stem Cell Mobilization"],"enrollment":99,"completionDate":"2026-08"},{"nctId":"NCT07258680","phase":"PHASE3","title":"BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2013-10","conditions":["Peripheral T-cell Lymphoma"],"enrollment":114,"completionDate":"2028-12"},{"nctId":"NCT06976112","phase":"NA","title":"Impact of Lean Pork on Endothelial Function in Perimenopause","status":"RECRUITING","sponsor":"Pennington Biomedical Research Center","startDate":"2025-08-01","conditions":["Cardiovascular Outcome","Overweight and Obese Women","Perimenopausal Women","Vasomotor Symptoms (VMS)"],"enrollment":30,"completionDate":"2027-05"},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":60,"completionDate":"2025-04-19"},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":["Lymphoma","Large B-Cell","Diffuse Large B-Cell"],"enrollment":127,"completionDate":"2024-12-31"},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":["Adult T-Cell Leukemia/Lymphoma","Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Angioimmunoblastic T-Cell Lymphoma","Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Hepatosplenic T-Cell Lymphoma","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":48,"completionDate":"2026-07-07"},{"nctId":"NCT04164472","phase":"NA","title":"NIH R01 Friend to Friend With Coaching","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-11-12","conditions":["Aggression"],"enrollment":5250,"completionDate":"2025-06-30"},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":62,"completionDate":"2027-01-16"},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":["Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":102,"completionDate":"2036-10"},{"nctId":"NCT06072131","phase":"PHASE3","title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","startDate":"2023-10-04","conditions":["Peripheral T Cell Lymphoma"],"enrollment":504,"completionDate":"2030-11"},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":["Relapsed/Refractory Follicular Lymphoma"],"enrollment":231,"completionDate":"2030-10"},{"nctId":"NCT07217002","phase":"","title":"Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-02-18","conditions":["Community Acquired Pneumonia (CAP)","Sinusitis","Strep Pharyngitis","Acute Otitis Media (AOM)"],"enrollment":420,"completionDate":"2029-05"},{"nctId":"NCT06587984","phase":"NA","title":"Influenza Reminder Text-Messaging","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2024-09-03","conditions":["Influenza"],"enrollment":228361,"completionDate":"2024-12-31"},{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":["Lymphoma"],"enrollment":30,"completionDate":"2010-10"},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":["Follicular Lymphoma"],"enrollment":1030,"completionDate":"2024-04-30"},{"nctId":"NCT05975671","phase":"NA","title":"Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-08-21","conditions":["Sepsis","Sepsis Mrsa","Sepsis Bacteremia","Antimicrobial - Induced Nephropathy","Sepsis, Severe","Septic Shock","Septic Syndrome"],"enrollment":52500,"completionDate":"2026-05"},{"nctId":"NCT07181785","phase":"","title":"Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2022-07-12","conditions":["Diffuse Large B Cell Lymphoma (DLBCL)"],"enrollment":555,"completionDate":"2023-07-12"},{"nctId":"NCT06947967","phase":"PHASE3","title":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2025-08-12","conditions":["Lymphoma, T-Cell, Peripheral"],"enrollment":224,"completionDate":"2032-12"},{"nctId":"NCT07011459","phase":"NA","title":"The Cooking for Health Optimization and Disease Prevention (CHOP) Trial","status":"RECRUITING","sponsor":"Tulane University","startDate":"2025-07-07","conditions":["Cardiovascular Diseases"],"enrollment":96,"completionDate":"2026-12"},{"nctId":"NCT00972478","phase":"PHASE1,PHASE2","title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-15","conditions":["Ann Arbor Stage II Non-Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma"],"enrollment":83,"completionDate":"2026-03-06"},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":899,"completionDate":"2027-11-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical"},"crossReferences":{"UNII":"G63QQF2NOX","SPL_ID":"41d661c2-82f9-0a2d-e063-6294a90a49ee"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Good for the Goose Products, LLC","relationship":"Original Developer"}],"publicationCount":16353,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Good for the Goose Products, LLC","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Good for the Goose Products, LLC","companyId":"good-for-the-goose-products-llc","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":14,"withResults":7},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:34:42.179425+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}